TABLE 2.
Proportion and number of seroresponders to the vaccine strain (44/76) in the SBA
| Group | Variable | Result at the indicated time
|
||||
|---|---|---|---|---|---|---|
| 6 wk after 2nd dose | 6 wk after 3rd dose | 10 mo after 3rd dose | 6 wk after 4th dose | 1 yr after 4th dose | ||
| MenBvac | % Responders (95% CI) | 49 (42-55) | 61 (54-67) | 25 (19-31) | 90 (85-93) | 59 (51-66) |
| No. of responders/total no. of subjects | 109/224 | 132/218 | 51/208 | 181/202 | 110/188 | |
| Placebo | % Responders (95% CI) | 0 (0-3) | 0 (0-3) | 3 (1-8) | 4 (1-9) | 4 (1-11) |
| No. of responders/total no. of subjects | 0/118 | 0/116 | 3/109 | 4/107 | 4/94 | |